Which closed-end funds own Royalty Pharma Plc?
2 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $570K. Security type: common equity. Country: United States. CUSIP G7709Q104 · ISIN GB00BMVP7Y09 · ticker RPRX.
Holdings are historical filings (report dates Jun 30, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| SPXX Nuveen S&P 500 Dynamic Overwrite Fund | Covered Call / Option Income | 0.02% | $682K | 12,171 sh | $2.9B | NAV unavailable | Jun 30, 2026 |
| BRW Saba Capital Income & Opportunities Fund | U.S. Equity | -0.03% | $-113K | -1,926 sh | $351M | 17.8% discount | Jul 31, 2026 |
2 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: Royalty Pharma PLC.
Related securities from the same issuer
| Security | Type | Funds holding |
|---|---|---|
| Royalty Pharma PLC | common equity | 3 |
| Royalty Pharma plc | debt security | 2 |
| Royalty Pharma PLC | debt security | 1 |
Issuer-level search for “RPRX” → · Compare two funds’ portfolios →